ArticleNPJ primary care respiratory medicine2025
Associations of asthma with cardiometabolic diseases and multimorbidity: A cohort study in the UK Biobank.
Article in NPJ primary care respiratory medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Asthma and Multimorbidity Amongst Ethnic Minority Groups in High Income Countries.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Review
- Joint association of depression and physical activity with incident cardiometabolic multimorbidity (CMM) among middle-aged and older adults in China.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Asthma is associated with adverse cardiovascular outcomes, but little is known about its role in the development of cardiometabolic multimorbidity (CMM). We aimed to examine the associations of asthma with both incident and coexisting cardiometabolic diseases (CMDs), characterizing their patterns and transitions to CMM in men and women. This prospective cohort study, based on the UK Biobank, included 51,335 participants with asthma and 395,890 without asthma at baseline in 2006-2010. Participants were followed for the development of CMDs, including type 2 diabetes, coronary heart disease, and stroke, using primary care records, hospital admission and death register data, and self-reported medical information up to December 31, 2022. CMM was defined as the coexistence of two or more CMDs. We used Cox proportional hazards models and multi-state models to assess the associations of asthma with the incidence and transitions to CMDs and CMM among participants free of CMDs. During a median follow-up of 13.8 years, 60,033 participants (13.4%) developed CMD, of whom 7,048 (1.6%) progressed to CMM. Asthma was associated with increased risks of all incident CMDs and CMM (hazard ratio [HR] = 1.54, 95% confidence interval = 1.44-1.64), as well as CMD counts and CMM patterns (e.g., HR = 1.60 [1.50-1.71] for 2 CMDs, and HR = 1.70 [1.56-1.84] for comorbid type 2 diabetes and coronary heart disease). For the transitions from no CMD to first CMD, from first CMD to CMM, and from no CMDs to death, the hazard ratios were 1.29 (1.26-1.33), 1.20 (1.12-1.28), and 1.14 (1.09-1.18), respectively. All these associations were more pronounced in women. In summary, individuals with asthma were at increased risk of developing cardiometabolic diseases and progressing to cardiometabolic multimorbidity. Early prevention and management of asthma, with integration into cardiometabolic risk assessment, may be crucial for mitigating future cardiometabolic multimorbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.